Northwestern Mutual Wealth Management
CRSP icon

Northwestern Mutual Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$479K Sell
10,060
-1,386
-12% -$73.1K ﹤0.01% 1577
2025
Q4 		$600K Buy
11,446
+2,033
+22% +$122K ﹤0.01% 1468
2025
Q3 		$610K Buy
9,413
+2,033
+28% +$117K ﹤0.01% 1398
2025
Q2 		$359K Buy
7,380
+507
+7% +$19.6K ﹤0.01% 1517
2025
Q1 		$234K Buy
6,873
+2,949
+75% +$125K ﹤0.01% 1602
2024
Q4 		$154K Sell
3,924
-746
-16% -$35.2K ﹤0.01% 1758
2024
Q3 		$219K Buy
4,670
+64
+1% +$3.25K ﹤0.01% 1596
2024
Q2 		$249K Buy
4,606
+211
+5% +$12.2K ﹤0.01% 1495
2024
Q1 		$300K Buy
4,395
+2,002
+84% +$143K ﹤0.01% 1410
2023
Q4 		$150K Buy
2,393
+101
+4% +$5.58K ﹤0.01% 1614
2023
Q3 		$104K Buy
2,292
+62
+3% +$3.2K ﹤0.01% 1699
2023
Q2 		$125K Buy
2,230
+363
+19% +$20.6K ﹤0.01% 1629
2023
Q1 		$84.4K Buy
1,867
+503
+37% +$24.4K ﹤0.01% 1748
2022
Q4 		$55.4K Sell
1,364
-873
-39% -$46.3K ﹤0.01% 1879
2022
Q3 		$146K Buy
2,237
+1,316
+143% +$95.4K ﹤0.01% 1497
2022
Q2 		$56K Buy
921
+428
+87% +$25.2K ﹤0.01% 1874
2022
Q1 		$31K Sell
493
-285
-37% -$17.9K ﹤0.01% 2132
2021
Q4 		$59K Hold
778
– – ﹤0.01% 1920
2021
Q3 		$87K Sell
778
-78
-9% -$9.8K ﹤0.01% 1690
2021
Q2 		$139K Buy
856
+531
+163% +$64.6K ﹤0.01% 1465
2021
Q1 		$40K Buy
325
+275
+550% +$41.5K ﹤0.01% 1817
2020
Q4 		$8K Sell
50
-8
-14% -$946 ﹤0.01% 2254
2020
Q3 		$5K Buy
+58
New +$5.14K ﹤0.01% 2165

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northwestern Mutual Wealth Management's CRSP Position: Q1 2026 in Review

Northwestern Mutual Wealth Management reduced its CRISPR Therapeutics (CRSP) stake by 12% in Q1 2026, selling an estimated $73.1K and leaving 10,060 shares worth $479K. The position accounts for ﹤0.01% of the portfolio, ranked #1577.

Northwestern Mutual Wealth Management first reported a position in CRSP in Q3 2020 and has held it in 23 quarters since. The position peaked at $610K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Northwestern Mutual Wealth Management held 10,060 shares of CRISPR Therapeutics worth $479K as of Q1 2026.
  • Northwestern Mutual Wealth Management sold 1,386 CRISPR Therapeutics shares in Q1 2026, an estimated $73.1K.
  • CRISPR Therapeutics made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q1 2026, its #1577 holding.
  • Northwestern Mutual Wealth Management first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Northwestern Mutual Wealth Management's CRISPR Therapeutics position peaked at $610K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.